Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

  • Showing results for a modified search because your search retrieved no results.

Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator.

Ho BL, Chen CF, Lin RT, Liu CK, Chao AC.

Neurol Sci. 2016 Nov;37(11):1799-1805. Epub 2016 Jul 16.


Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.

Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM.

Vasc Health Risk Manag. 2014 Feb 24;10:75-87. doi: 10.2147/VHRM.S39213. eCollection 2014. Review.


A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

Adeoye O, Knight WA, Khoury J, Schmit PA, Sucharew H, Broderick JP, Pancioli AM; CLEAR-ER Investigators..

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e313-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.012. Epub 2014 Feb 15.


Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:., Levine SR, Khatri P, Broderick JP, Grotta JC, Kasner SE, Kim D, Meyer BC, Panagos P, Romano J, Scott P; NINDS rt-PA Stroke Trial Investigators..

Stroke. 2013 Sep;44(9):2500-5. doi: 10.1161/STROKEAHA.113.000878. Epub 2013 Jul 11. Review. Erratum in: Stroke. 2014 Mar;45(3):e52.


Advances in revascularization for acute ischemic stroke treatment: an update.

Eesa M, Schumacher HC, Higashida RT, Meyers PM.

Expert Rev Neurother. 2011 Aug;11(8):1125-39. doi: 10.1586/ern.11.102. Review.


Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.

Hassan AE, Hassanzadeh B, Tohidi V, Kirmani JF.

South Med J. 2010 May;103(5):398-402. doi: 10.1097/SMJ.0b013e3181d7814a.


Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.

Rhoney DH, Coplin WM, Lin Y, Frankel M, Lyden PD, Levine SR.

J Stroke Cerebrovasc Dis. 2010 Jan;19(1):40-8. doi: 10.1016/j.jstrokecerebrovasdis.2009.03.006.


The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.

Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators..

Stroke. 2008 Dec;39(12):3268-76. doi: 10.1161/STROKEAHA.108.517656. Epub 2008 Sep 4.


[Alteplase treatment for acute stroke 2007: an effective therapeutic option at our disposal].

Carneado-Ruiz J, Saver JL.

Rev Neurol. 2007 Jul 1-15;45(1):42-52. Review. Spanish.


Thrombolytic therapy for acute ischemic stroke.

Canadian Association of Emergency Physicians Committee on Thrombolytic Therapy for Acute Ischemic Stroke..

CJEM. 2001 Jan;3(1):8-12.


Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.

Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR; NINDS rt-PA Stroke Study Group..

Stroke. 2006 Oct;37(10):2508-13. Epub 2006 Sep 7.


Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).

Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group..

Stroke. 2006 Jul;37(7):1810-5. Epub 2006 Jun 8.


Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.

National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group..

Ann Emerg Med. 2005 Sep;46(3):243-52.


Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.

Schwammenthal Y, Drescher MJ, Merzeliak O, Tsabari R, Bruk B, Feibel M, Hoffman C, Bakon M, Rotstein Z, Chapman J, Tanne D.

Isr Med Assoc J. 2004 Feb;6(2):70-4.


Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.

Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE; NINDS rt-PA Stroke Study Group..

Neurology. 2002 Sep 10;59(5):669-74.


Thrombolysis in patients with transient neurologic deficits.

Lyden P, Lu M, Kwiatkowski T, Frankel M, Levine S, Broderick J, Brott T; NINDS rt-PA Stroke Study Group..

Neurology. 2001 Dec 11;57(11):2125-8.


Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.

Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group..

JAMA. 2001 Dec 12;286(22):2830-8.


Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.

Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T.

Neurology. 2000 Oct 10;55(7):952-9.


Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis?

Rudolf J, Neveling M, Grond M, Schmulling S, Stenzel C, Heiss WD.

Eur J Neurol. 1999 Jan;6(1):51-5.


Supplemental Content

Loading ...
Support Center